Literature DB >> 10217612

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants.

U Schröder1, S B Svenson.   

Abstract

A novel suspension system was developed where monoglycerides were formulated together with fatty acids and subsequently admixed with antigens. In the present study, diphtheria toxoid was used as a model antigen primarily due to its weak immunological properties as well as to its importance as a future human vaccine for mucosal, particularly nasal immunization. The formulations were administered parenterally and/or nasally to mice whereafter the immune response was determined. In the present study, we have shown that mono-olein/oleic acid vesicles enhance the immunogenicity of admixed diphtheria toxoid in mice to the same level as Alum adsorbed (or Freund's complete adjuvant) when administered parenterally or nasally. It was also shown that the immunogenicity was linked to the length of the acyl chain of the lipids, where shorter acyl chains resulted in reduced titers. Furthermore, shorter acyl chains also gave rise to more pronounced toxic reactions at the injections sites, such as necrosis and alopeci, both of which were lacking when the optimal formulation consisting of mono-olein and oleic acid was used. Thus, this lipid matrix has in our view a great potential as an immunological adjuvant with an exceptionally simple and efficient preparation procedure without organic solvents and with low cost endogenous lipid based raw materials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217612     DOI: 10.1016/s0264-410x(98)00408-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.

Authors:  Anshuman Shukla; Bhupinder Singh; O P Katare
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein.

Authors:  Anirban Sengupta; Mohammad Azharuddin; Maria E Cardona; Claudia Devito; Eleanore von Castelmur; Anna Wehlin; Zuzanna Pietras; Maria Sunnerhagen; Robert Selegård; Daniel Aili; Ali Alamer; Jorma Hinkula; Noha Al-Otaibi
Journal:  Vaccines (Basel)       Date:  2022-03-24

3.  Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Authors:  Tina Falkeborn; Andreas Bråve; Marie Larsson; Britt Akerlind; Ulf Schröder; Jorma Hinkula
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

4.  Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice.

Authors:  Jorma Hinkula; Sanna Nyström; Claudia Devito; Andreas Bråve; Steven E Applequist
Journal:  Vaccines (Basel)       Date:  2019-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.